EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieLeitlinie

Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?

Jingjing Qian iD, Asmita P Khatiwada iD, Xiangzhong Xue

The American Journal on Addictions · 2024

DOI: 10.1111/ajad.13505 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The American Journal on Addictions, 2024. Verfasst von Jingjing Qian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, Alabama, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives In April 2021, the Department of Health and Human Services released new federal practice guidelines and allowed physicians who wish to treat ≤30 patients with opioid use disorder (OUD) to forego the X‐waiver training requirement.

Methods

This observational study compared annual number, dose, and spending of buprenorphine OUD treatments dispensed in the Medicaid population in 2021 versus 2020 using the CMS State Drug Utilization Data ( n = 50 states plus D.C.).

Results

Compared to 2020, there was a slight decrease (−3.1%) in the annual number of buprenorphine prescriptions dispensed but an increase in total doses (+3.2%) and payment (10.6%) for buprenorphine prescriptions in 2021. Discussion and Conclusions Decrease in number of buprenorphine prescriptions in Medicaid population was observed in 2021. Scientific Significance Our findings support the hypothesis generation in which the removal of X‐waiver training alone is not adequate to increase prescribing and access to OUD treatment buprenorphine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersHumansMedicaidNarcotic AntagonistsOpiate Substitution TreatmentPrescriptionsUnited States

Substanzen

BuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, Alabama, USA.

ORCID-Profile: Jingjing Qian, Asmita P Khatiwada

Zitieren

APA

Qian, J., Khatiwada, A. P., & Xue, X. (2024). Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?. The American Journal on Addictions. https://doi.org/10.1111/ajad.13505

Vancouver

Qian J, Khatiwada AP, Xue X. Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?. The American Journal on Addictions. 2024. doi:10.1111/ajad.13505

BibTeX
@article{Qian2024,
  author = {Qian, Jingjing and Khatiwada, Asmita P and Xue, Xiangzhong},
  title = {Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?},
  journal = {The American Journal on Addictions},
  year = {2024},
  doi = {10.1111/ajad.13505}
}
Kostenlos starten →